Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Shin-ya Kawashiri, Atsushi Kawakami, Naoki Iwamoto, Keita Fujikawa, Toshiyuki Aramaki, Mami Tamai, Satoshi Yamasaki, Hideki Nakamura, Tomoki Origuchi, Yukitaka Ueki, Kiyoshi Migita, Akinari Mizokami, Kiyoshi Aoyagi & Katsumi Eguchi. (2011) In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline. Modern Rheumatology 21:4, pages 370-374.
Read now
Read now
Shin-ya Kawashiri, Atsushi Kawakami, Naoki Iwamoto, Keita Fujikawa, Toshiyuki Aramaki, Mami Tamai, Satoshi Yamasaki, Hideki Nakamura, Yukitaka Ueki, Kiyoshi Migita, Akinari Mizokami, Tomoki Origuchi, Kiyoshi Aoyagi & Katsumi Eguchi. (2011) Disease activity score 28 may overestimate the remission induction of rheumatoid arthritis patients treated with tocilizumab: comparison with the remission by the clinical disease activity index. Modern Rheumatology 21:4, pages 365-369.
Read now
Read now
Articles from other publishers (21)
Julia Lehmann, Stavros Giaglis, Diego Kyburz, Douglas Daoudlarian & Ulrich A. Walker. (2024) Plasma mtDNA as a possible contributor to and biomarker of inflammation in rheumatoid arthritis. Arthritis Research & Therapy 26:1.
Crossref
Crossref
Nozima Aripova, Joel M Kremer, Dimitrios A Pappas, George Reed, Bryant R England, Bill H Robinson, Jeffrey R Curtis, Geoffrey M Thiele & Ted R Mikuls. (2024) Anti-citrullinated protein antibody profiles predict changes in disease activity in patients with rheumatoid arthritis initiating biologics. Rheumatology 63:2, pages 542-550.
Crossref
Crossref
Takayuki Fujii, Koichi Murata, Hideo Onizawa, Akira Onishi, Masao Tanaka, Kosaku Murakami, Kohei Nishitani, Moritoshi Furu, Ryu Watanabe, Motomu Hashimoto, Hiromu Ito, Takao Fujii, Tsuneyo Mimori, Akio Morinobu & Shuichi Matsuda. (2024) Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. Arthritis Research & Therapy 26:1.
Crossref
Crossref
Ashok Kumar, Rahul Rudrakar & Kushagra Gupta. (2023) A Retrospective Study on Clinical Experience with Tofacitinib in the Treatment of Rheumatoid Arthritis at a Tertiary Care Center. Indian Journal of Rheumatology.
Crossref
Crossref
Alison K. Spencer, Jigar Bandaria, Michelle B. Leavy, Benjamin Gliklich, Zhaohui Su, Gary Curhan & Costas Boussios. (2021) Validation of a machine learning approach to estimate Clinical Disease Activity Index Scores for rheumatoid arthritis. RMD Open 7:3, pages e001781.
Crossref
Crossref
Dimitrios A. Pappas, Christine Brittle, James E. MossellIIIIII, Johanna B. Withers, Jeraldine Lim-Harashima & Joel M. Kremer. (2020) Perceived clinical utility of a test for predicting inadequate response to TNF inhibitor therapies in rheumatoid arthritis: results from a decision impact study. Rheumatology International 41:3, pages 585-593.
Crossref
Crossref
Ahmad Y. Abuhelwa, Ashley M. Hopkins, Michael J. Sorich, Susanna Proudman, David J. R. Foster & Michael D. Wiese. (2020) Association between obesity and remission in rheumatoid arthritis patients treated with disease-modifying anti-rheumatic drugs. Scientific Reports 10:1.
Crossref
Crossref
Tate M. Johnson, Kaleb Michaud & Bryant R. England. (2020) Measures of Rheumatoid Arthritis Disease Activity. Arthritis Care & Research 72:S10, pages 4-26.
Crossref
Crossref
Fabio Massimo Perrotta, Antonia De Socio, Silvia Scriffignano & Ennio Lubrano. (2018) Residual disease activity in rheumatoid arthritis patients treated with subcutaneous biologic drugs that achieved remission or low disease activity: a longitudinal observational study. Clinical Rheumatology 37:6, pages 1449-1455.
Crossref
Crossref
Worawit Louthrenoo, Nuntana Kasitanon, Wanruchada Katchamart, Duangkamol Aiewruengsurat, Parawee Chevaisrakul, Praveena Chiowchanwisawakit, Pornchai Dechanuwong, Punchong Hanvivadhanakul, Ajanee Mahakkanukrauh, Siriporn Manavathongchai, Chayawee Muangchan, Pongthorn Narongroeknawin, Veerapong Phumethum, Boonjing Siripaitoon, Anawat Suesuwan, Siraphop Suwannaroj, Parichat Uea‐Areewongsa, Sittichai Ukritchon, Paijit Asavatanabodee, Ajchara Koolvisoot, Ratanavadee Nanagara, Kitti Totemchokchyakarn, Kanokrut Nuntirooj & Tasanee Kitumnuaypong. (2017) 2016 updated Thai Rheumatism Association Recommendations for the use of biologic and targeted synthetic disease‐modifying anti‐rheumatic drugs in patients with rheumatoid arthritis. International Journal of Rheumatic Diseases 20:9, pages 1166-1184.
Crossref
Crossref
Mohammed A. Omair, Edward Keystone, Vivian Bykerk, Daming Lin, Juan Xiong, Ye Sun, Gilles Boire, J. Carter Thorne, Diane Tin, Janet Pope, Carol Hitchon, Boulos Haraoui & Pooneh S. Akhavan. (2017) Predicting Low Disease State and Remission in Early Rheumatoid Arthritis in the First Six Months, Comparing the Simplified Disease Activity Index and European League Against Rheumatism Response Measures: Results From an Early Arthritis Cohort. Arthritis Care & Research 69:5, pages 737-741.
Crossref
Crossref
Inger Marie Jensen HansenRikke Asmussen AndreasenMark Nam van Bui HansenAmir Emamifar. (2017) The Reliability of Disease Activity Score in 28 Joints–C-Reactive Protein Might Be Overestimated in a Subgroup of Rheumatoid Arthritis Patients, When the Score Is Solely Based on Subjective Parameters. JCR: Journal of Clinical Rheumatology 23:2, pages 102-106.
Crossref
Crossref
Emilce Edith Schneeberger, Natalia Zamora & Gustavo Citera. (2016) SASDAS (simplified version of ankylosing spondylitis disease activity score)-ESR performance and development of SASDAS-CRP and their agreement with ASDAS-ESR and ASDAS-CRP in patients with ankylosing spondylitis. Clinical Rheumatology 35:11, pages 2865-2866.
Crossref
Crossref
Marta Maria das Chagas Medeiros, Brenda Maria Gurgel Barreto de Oliveira, João Victor Medeiros de Cerqueira, Raquel Telles de Souza Quixadá & Ídila Mont’Alverne Xavier de Oliveira. (2015) Correlation of rheumatoid arthritis activity indexes (Disease Activity Score 28 measured with ESR and CRP, Simplified Disease Activity Index and Clinical Disease Activity Index) and agreement of disease activity states with various cut-off points in a Northeastern Brazilian population. Revista Brasileira de Reumatologia (English Edition) 55:6, pages 477-484.
Crossref
Crossref
Marta Maria das Chagas Medeiros, Brenda Maria Gurgel Barreto de Oliveira, João Victor Medeiros de Cerqueira, Raquel Telles de Souza Quixadá & Ídila Mont’Alverne Xavier de Oliveira. (2015) Correlação dos índices de atividade da artrite reumatoide (Disease Activity Score 28 medidos com VHS, PCR, Simplified Disease Activity Index e Clinical Disease Activity Index) e concordância dos estados de atividade da doença com vários pontos de corte numa população do nordeste brasileiro. Revista Brasileira de Reumatologia 55:6, pages 477-484.
Crossref
Crossref
Gábor Futó, Attila Somogyi & Zoltán Szekanecz. (2014) Visualization of DAS28, SDAI, and CDAI: the magic carpets of rheumatoid arthritis. Clinical Rheumatology 33:5, pages 623-629.
Crossref
Crossref
Bernhard Rintelen, Judith Sautner, Pia Haindl, Harsono Mai, Hans-Peter Brezinschek & Burkhard F. Leeb. (2013) Remission in Rheumatoid Arthritis: A Comparison of the 2 Newly Proposed ACR/EULAR Remission Criteria with the Rheumatoid Arthritis Disease Activity Index-5, a Patient Self-report Disease Activity Index. The Journal of Rheumatology 40:4, pages 394-400.
Crossref
Crossref
Yvonne M. R. de Punder, Jaap Fransen, Wietske Kievit, Pieternella M. Houtman, Henk Visser, Mart A. F. J. van de Laar & Piet L. C. M. van Riel. (2012) The prevalence of clinical remission in RA patients treated with anti-TNF: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry. Rheumatology 51:9, pages 1610-1617.
Crossref
Crossref
P. H. P. de Jong, J. M. W. Hazes, D. van Zeben, P. A. van der Lubbe, M. H. de Jager, P. B. de Sonnaville, J. J. Luime & A. E. A. M. Weel. (2012) Treatment decisions and related costs differ significantly depending on the choice of a disease activity index in RA, according to 1987 and 2010 classification criteria. Rheumatology 51:7, pages 1269-1277.
Crossref
Crossref
BINDEE KURIYA, YE SUN, GILLES BOIRE, BOULOS HARAOUI, CAROL HITCHON, JANET E. POPE, JOHN C. THORNE, EDWARD C. KEYSTONE & VIVIAN P. BYKERK. (2012) Remission in Early Rheumatoid Arthritis — A Comparison of New ACR/EULAR Remission Criteria to Established Criteria. The Journal of Rheumatology 39:6, pages 1155-1158.
Crossref
Crossref
H. Singh, H. Kumar, R. Handa, P. Talapatra, S. Ray & V. Gupta. (2011) Use of Clinical Disease Activity Index Score for Assessment of Disease Activity in Rheumatoid Arthritis Patients: An Indian Experience. Arthritis 2011, pages 1-5.
Crossref
Crossref